BRD9 Degrading Compounds for BAF Complex Disorders
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for disorders related to the BAF complex, such as cancer and infections, lack effective methods to target BRD9, a component of the BAF complex, particularly in reducing its levels or activity.
Innovation Solution
Development of specific compounds that degrade BRD9, including those with structures defined by Formula I and Formula II, which can be used to treat BAF-related disorders by depleting BRD9 levels, thereby affecting the SS18-SSX fusion protein and cellular antiviral activities.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments are used for BAF complex-related disorders, then existing therapeutic approaches are maintained, but effective targeting of BRD9 to reduce its levels or activity is not achieved
Solution Approach 1:
The patent employs proteolysis targeting chimeras (PROTACs) that induce ubiquitination and proteasomal degradation of BRD9, fundamentally changing the therapeutic parameter from inhibition to degradation. This approach reduces BRD9 protein levels directly, overcoming the limitations of existing treatments that cannot effectively target BRD9 reduction.
2Reliability
If BRD9 levels are reduced using degradation compounds, then treatment effectiveness for cancer and infections is improved, but the complexity of the therapeutic approach increases
Solution Approach 1:
The patent uses PROTAC molecules as intermediary agents that facilitate BRD9 degradation. These chimeric compounds consist of a BRD9 ligase domain, a linker, and a recruitment domain that binds to an E3 ubiquitin ligase. The intermediary PROTAC mediates the interaction between BRD9 and the degradation machinery, achieving effective BRD9 reduction while maintaining a manageable therapeutic approach.
3Adaptability or versatility
If specific compounds are developed to degrade BRD9, then the ability to treat synovial sarcoma and other BAF-related disorders is enhanced, but the manufacturing and development process becomes more complex
Solution Approach 1:
The PROTAC molecules are segmented into distinct functional domains: a BRD9 ligase domain (bromodomain-binding region), a linker region, and a recruitment domain (E3 ligase-binding region). This segmentation allows for modular optimization of each domain independently, facilitating structure-activity relationship studies and enabling systematic improvement of binding affinity and degradation efficacy while simplifying the development process.
Data Source
AI summary
The present invention relates to compositions and methods for the treatment of BAF-related disorders, such as cancers and viral infections.